Get the Stockscreener App
16.68
2.58%
-0.36
Pharvaris Nv stock is traded at $16.68, with a volume of 10,535.
It is down -2.58% in the last 24 hours and up +34.96% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$17.04
Open:
$17.15
24h Volume:
10,535
Relative Volume:
0.17
Market Cap:
$972.70M
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-5.9074
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-9.64%
1M Performance:
+34.96%
6M Performance:
-26.58%
1Y Performance:
-19.30%
1-Day Range:
$16.74
$17.27
1-Week Range:
$16.18
$19.07
52-Week Range:
$11.51
$25.50
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
16.74 | 972.70M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.18 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
551.67 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.18 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.62 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World
When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com
Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World
Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World
Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World
Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com
JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK
Where are the Opportunities in (PHVS) - news.stocktradersdaily.com
What is Leerink Partnrs’ Forecast for Pharvaris Q1 Earnings? - The AM Reporter
5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World
What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World
Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World
What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World
Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView
Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks
Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan
Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World
(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener
Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan
(PHVS) Technical Data - news.stocktradersdaily.com
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):